Description: CARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.
Home Page: cargo-tx.com
1900 Alameda De Las Pulgas
San Mateo,
CA
94403
United States
Phone:
650 379 6143
Officers
| Name | Title |
|---|---|
| Ms. Gina Chapman | President, CEO & Director |
| Dr. Crystal L. Mackall M.D. | Co-Founder & Scientific Advisory Board Chair |
| Mr. Anup Radhakrishnan | CFO, Secretary & COO |
| Dr. Ginna G. Laport M.D. | Chief Medical Officer |
| Dr. Robbie Majzner M.D. | Co-Founder & Scientific Advisory Board Member |
| Ms. Nancy Goodman J.D. | Founder |
| Dr. Louai Labanieh | Founder |
| Mr. Faisal Shawwa M.B.A. | Senior Vice President of Finance & Accounting |
| Dr. Shishir Gadam Ph.D. | Chief Technical Officer |
| Dr. Michael Ports Ph.D. | Chief Scientific Officer |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 1.7154 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2023-11-10 |
| Fiscal Year End: | December |
| Full Time Employees: | 170 |